News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major news in the past hour; no market-moving headlines emerged.
  • Market trading subdued as investors awaited scheduled data and earnings.
  • Equity futures largely unchanged without fresh catalysts.
  • Treasury yields moved little amid muted risk sentiment.
  • Dollar showed limited movement against major currencies.
  • Energy and commodity prices stabilized in absence of supply or demand headlines.

Latest Articles

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, announced its management's participation in key August biotech conferences to discuss clinical progress and company strategy.

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics, a clinical-stage healthcare company focused on CNS cancers, announced upcoming presentations of its ReSPECT-LM clinical program and CNSide diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference. The company will also host a sponsored symposium on leptomeningeal metastases management. Additionally, Plus Therapeutics wi…

Hubbell Reports Second Quarter 2026 Results

Hubbell Reports Second Quarter 2026 Results

Hubbell Incorporated (NYSE: HUBB) delivered solid Q2 2026 performance, reporting a 15% increase in net sales and a 12% rise in adjusted diluted EPS to $5.52. Organic sales growth was driven by strong demand in utility solutions and electrical solutions segments, fueled by megatrends like grid modernization and datacenter investments. Adjusted opera…

Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada

Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada

Venus Concept Inc., a leader in medical aesthetic technology, has obtained exclusive rights to distribute HIRONIC's Doublo 2.0 device in the United States and Canada. The new device, which incorporates Cold Plasma and RF microneedling technologies, has received FDA 510(k) clearance and will be launched in the US in the second half of 2026. Venus Co…

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on novel therapies for rare skin diseases and vascular malformations, will announce its Q2 2026 financial results before market open on August 4, 2026, followed by a corporate update conference call. The company is developing therapies based on its QTORIN platform, with lead …

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics announces FDA clearance of its Investigational New Drug application for DYNE-302, advancing its third clinical program leveraging the FORCE platform to treat facioscapulohumeral muscular dystrophy (FSHD), a rare progressive neuromuscular disorder with no approved therapies. The Phase 1 trial will assess safety, tolerability, pharm…

Riot Announces Second Quarter 2026 Earnings Conference Call

Riot Announces Second Quarter 2026 Earnings Conference Call

Riot Platforms, Inc., a leader in large-scale data centers and bitcoin mining, announced its Q2 2026 earnings call set for August 5, 2026. The company focuses on developing digital infrastructure and mining operations across Texas and Kentucky, with engineering facilities in Denver and Houston. The press release reiterates forward-looking statement…

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma, a clinical-stage biopharmaceutical company developing innovative intranasal therapies, announced the appointment of pharmaceutical industry veteran Brendan P. O'Grady as CEO. O'Grady will lead the next phase of growth with an emphasis on unlocking the commercial potential of NS002, an intranasal epinephrine treatment targeting a $2 bi…

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc., through its subsidiary A&B Aerospace, has entered a long-term manufacturing agreement with Precision Aerospace & Defense Group to supply precision-machined aerospace and defense components. Additionally, PMGC made a $500,000 strategic equity investment in PAD Group, further aligning their partnership. This collaboration position…

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported robust second quarter 2026 financial results highlighted by 55% year-over-year net product revenue growth for ARCALYST®, reaching $243.6 million in Q2. The company raised its full-year 2026 ARCALYST revenue guidance to $980-$995 million. Clinical progress continues with promising Phase 2 data for KPL-387 supporting …

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

Digital Currency X Technology Inc. has announced comprehensive upgrades to its DexTrader on-chain data platform, enhancing data architecture, omnichain capabilities, and user services. The company aims to target the digital asset information niche for token-based derivatives, yield instruments, and collateralized assets, positioning DexTrader as a …

PayPal reiterates turnaround amid takeover debate after a pivotal quarter

PayPal reiterates turnaround amid takeover debate after a pivotal quarter

PayPal pushed forward with an aggressive turnaround program after reporting a quarter that outperformed expectations, increasing its 2026 profit projection and detailing multi-year cost, organizational and technology initiatives. The moves come as the company faces a $60.50-per-share takeover bid that its board has deemed insufficient and as compet…

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical announced three new customer agreements, including a late-stage regenerative medicine program and two early-stage projects supporting medical technology development. These agreements diversify Lifecore's pipeline and are expected to contribute to revenue starting in 2028, reinforcing its position as a key player in the CDMO mark…

AZZ: Secular Demand and Lower Leverage Make a Convincing Long Setup

AZZ: Secular Demand and Lower Leverage Make a Convincing Long Setup

AZZ Inc. combines structural demand for corrosion protection and power transmission with a cleaner balance sheet and improving margins. Management's FY27 guidance (sales $1.73-$1.78B, adj. EBITDA up to $400M, adj. EPS up to $7.00) plus steady free cash flow ($169M last reported) supports upside from the current price. Trade idea: enter $149.00, sto…